Primary immunodeficiencies (PIDs) represent a large group of disorders with an increased susceptibility to infections. Severe combined immunodeficiency (SCID) is the most severe form of primary immunodeficiencies (PIDs) with marked Tcell lymphopenia. Investigation of the genetic aetiology using classical Sanger sequencing is associated with considerable diagnostic delay. We here established a custom-designed, next-generation sequencing (NGS)-based panel to efficiently identify disease-causing genetic defects in PID patients and applied this method in SCID patients of Turkish origin with previously undefined genetic aetiology. We used HaloPlex enrichment technology, a targeted, NGS-based method which was designed to diagnose patients with SCID and other PIDs. Our HaloPlex panel included a total of 356 PID-related genes, and we searched disease-causing mutations in 19 Turkish SCID patients without a genetic diagnosis. The coverage of targeted regions ranged from 97.47% to 99.62% with an average of 98.31% for all patients. All known SCID genes were covered with a percentage of at least 97.3%. We made a genetic diagnosis in six of 19 (33%) patients, including four novel disease-causing mutations identified in RAG1, JAK3 and IL2RG, respectively. We showed that this NGS-based method can provide rapid genetic diagnosis for patients suffering from SCID, potentially facilitating clinical treatment decisions.
Introduction
Primary immunodeficiencies (PIDs) comprise a heterogeneous group of disorders caused by mutations in genes that play a role in the development and/or function of the immune system [1] . PID patients present with a wide range of clinical symptoms, including high susceptibility to infections, autoimmunity, inflammation, allergy and malignancies [2] . The vast majority of PIDs known at present are monogenic disorders, mostly following the rules of Mendelian inheritance. So far, genetic defects in more than 300 genes have been shown to cause immunodeficiencies [3] ; however, the identification of causative gene defects in individual patients remains challenging. Mutations in different genes can manifest with similar clinical symptoms, and conversely, different mutations in the same gene may cause distinct disease phenotypes. Furthermore, the variability of clinical phenotypes of a PID can present differently even in patients who have exactly the same genetic defect probably due to environmental or epigenetic factors [4] . Although in general PID prevalence is low and ranges between 1:5,000,000 and 1:100,000, in some countries such as Turkey, high rates of consanguinity lead to a higher incidence of PIDs [5] [6] [7] .
Severe combined immunodeficiency (SCID) is the most severe form of PID. It is characterized by severe reduction in T and/or B lymphocytes depending on the underlying gene mutation [8] . Children with SCID have a dramatically increased susceptibility to severe infections already very early in life with often fatal outcome. Although some gene therapy trials have been proceeding for particular genetic defects such as ADA and IL2RG deficiency [9] , hematopoietic stem cell transplantation (HSCT) is the only curative treatment to date [10] . Identification of the underlying genetic disease cause is critically important to estimate the natural disease history, provide genetic counselling, and may influence clinical treatment decisions, e.g. condition regimen for allogeneic hematopoietic stem cell transplantation [11, 12] . Given that a considerable number of more than 30 genetic defects can cause SCID and related disorders, Sanger sequencingbased approaches can be tedious and relatively expensive. Today, novel technologies based on next-generation sequencing allow for identification of new genetic defects at an ever-increasing rate [13] , thus enabling simultaneous genetic analyses of a number of selected genes or the whole genomes at an affordable cost. Herein we applied an NGSbased targeted sequencing approach as an alternative to provide more rapid and cost-effective diagnosis [14] . The gene panel comprises a total of 356 PID genes, which include all known SCID-causing genes. With this method, we were able to diagnose six patients of a clinically welldefined cohort, which suggests that several novel gene defects are yet to be discovered in SCID patients; particularly in consanguineous populations where autosomal recessive defects are suspected.
Material and methods
Patients. This study included 19 patients of Turkish origin fulfilling criteria [15] for diagnosing SCID (ten T-BÀ SCID, nine T-B+ SCID) without a genetic diagnosis. Four patients with known variants [a RAG1 variant in chromosomal position 3659662 (c.1879C>G), an AICDA variant in chromosomal position 8765447 (c.21T>C), an IL10RA variant in chromosomal position 117864047 (c.740G>A), an IL10RB variant in chromosomal position 34640788 (c.247A>G)] served as positive controls. All patients were diagnosed with SCID according to their clinical and laboratory findings at Hacettepe University, Ihsan Do gramacı Children's Hospital, Department of Immunology, Ankara. Clinical findings are summarized in Table 1 . Several SCID genes were excluded in six patients by Sanger sequencing before subjecting these samples to the present study (Table S1 ).
The study was approved by the ethics committee of the Medical University of Vienna and University of Hacettepe. All patient material was obtained in accordance with the Declaration of Helsinki.
DNA Isolation and preparation. Germany). Genomic DNA (gDNA) samples were digested with eight pairs of restriction enzymes to create a library of gDNA restriction fragments. To validate the restriction digestion reaction, we analysed the enrichment control DNA (ECD) sample using microfluidic electrophoresis on 2100 Bioanalyzer (Agilent Technologies Inc.). Restricted fragments were pooled and hybridized with customized probes hybridizing to exons and 25-bp flanking regions of the selected genes. As outlined above, HaloPlex TM probes were designed to capture 356 PID-related genes. Circularized target DNA-HaloPlex probe hybrids, containing biotin, were captured with streptavidin-coated magnetic beads and DNA ligase was added to the capture reaction to close nicks in the circularized probe-target DNA hybrids. Subsequently, we amplified the samples by PCR and purified using AMPure XP beads (Beckman Coulter, Inc., Krefeld, Germany). Prior to sample pooling, the quality of the library was inspected using 2100 Bioanalyzer (Agilent Technologies Inc., Eindhoven, Netherlands). A multiplexed 100-bp paired-end-read sequencing was carried out on Illumina HiSeq2000 (Illumina Inc., Eindhoven, Netherlands) Sequencer running on HISEQ CONTROL Software (HCS) 1.4.8, REAL-TIME ANALYSIS Software (RTA) 1.12.4.2.
Data analysis. The data analysis was carried out using Burrows-Wheeler Aligner to align the reads to the human genome 19 (hg19). Insertion/deletion realignment was performed as well as GATK (Genome Analysis Toolkit, Broad Institute, MIT) base quality score recalibration. For single nucleotide variant (SNV) and insertion/deletion calling, Unified Genotyper and GATK Variant quality score recalibration was performed. Variants were called, and the variant effects predicted using SNPEFF software [16] . Variants with a minor allele frequency of more than 0.01 were excluded, and lists were further filtered for rare nonsense and missense variants within the exons as well as splice-site variants of the targeted genes (Fig. S1 ).
Coverage. We used GATK CallableLoci (Broad Institute, MIT) tool to detect the callable base pair positions of the targeted exons. This tool considers coverage at each locus and releases a per base state and a summary interval BED file. These genomic intervals were divided into the following callable states: Ref N, pass, no coverage, low coverage, excessive coverage and poor mapping quality. Any locus was considered callable with a minimum read depth of 20 and a mapping quality score reaching at least 10.
Variant validations. Variant validation by capillary sequencing was performed according to standard methods as previously described [17] .
Results
We investigated underlying genetic defects of a total of 19 Turkish patients diagnosed with SCID using a novel NGSbased technology for targeted enrichment of genomic regions. We employed a target enrichment strategy to enable simultaneous analysis of genomic regions of interest in a large number of samples. We designed a sequencing panel that targeted 356 PID-related genes including all known SCID and combined immunodeficiency (CID) genes. The total of 356 PID-related genes comprised 218 previously reported causative genes [3] and additional PIDrelated genes recently published or presented at scientific conferences at the time of the gene panel design, as well as several genes suspected to cause immunodeficiency.
The targeted sequencing step of our study was completed in 3 weeks. Including data analysis steps and validation of candidate gene defects by Sanger sequencing, the entire process lasted 2 months. Prize comparison of our NGS-based SCID study with conventional Sanger sequencing shows a clear financial benefit for the panel approach (data not shown).
Among the sequenced patients, we detected a total of eight variants that could be potentially responsible for the clinical phenotypes of the patients (Table 2) . Of these eight variants, seven were considered disease-causing genetic defects based on the respective patients' phenotype. Finally, we made a genetic diagnosis in six of 19 patients (32%). All mutations reported here were found in known SCID genes; however, four of those were previously not described (Fig. 1) . Detection of known variants in positive control samples is one important parameter which reflects the reliability of NGS-based methods. For this purpose, we have included four samples with described variants that were Sanger validated beforehand. All known variants in these positive control samples were detected as well. The number of uniquely mapped reads per sample ranged between 1,667,214 and 6,739,674 with the mean value of 3,973,000 (AE1,258,000) reads. The coverage of targeted regions with at least 49 depth and the mapping quality score above 10 ranged from 97.47% to 99.62% with an average of 98.31% for all samples analysed (Table S2 ). These data indicate that the targeted genes were highly covered with good quality. We calculated the coverage of classical SCID genes (according to IUIS classification) [3] . With exception of exon 11 of CORO1A, all SCID genes were covered between 97.3%-100% ( Fig. 2 and Table S3 ). CORO1A has several paralogs [18] and due to a gene duplication the mapping quality score was 0 in this region. In addition, the coverage of 13 genes leading to severe phenotypes like SCID was calculated. These genes were also covered sufficiently (98.91%-100%) (Table S3 and Fig. S2 ). Despite the high overall coverage of the targeted region, the following genes were not well covered: C4B, FCGR1A, FCGR3A, CFH, GCC2, LTF, STK19, PMS2, NCF1, SPDYE5, IGH, CORO1A, HYDIN, STAT5B and IKBKG. Of those, NCF1, C4B, FCGR1A and IKBKG were found to be insufficiently covered in the study of Nijman et al., [19] most likely due to high GC content or close proximity to pseudogenes.
Likely disease-causing mutations were found in RAG1, JAK3 and IL2RG genes. Four novel mutations were detected in the same three genes, as well. A novel homozygous mutation in RAG1 (c.2259G>A) was found in patient 2. Potential damaging effects of this variant were found to be 'possibly damaging' in PolyPhen (score: 0.877) and 'deleterious' in SIFT (score: 0), respectively. This mutation causes an amino acid change of arginine to glycine at highly conserved position 716 in the core of RAG1 protein which interacts with RAG2 [20] . Additionally, two previously unknown mutations in the JAK3 gene (c.1898G>A and c.1383_1384insG) were detected in patients 3 and 7. A single nucleotide variant detected in patient 3 leading to a premature stop codon. The other JAK3 mutation found in patient 7 was a single nucleotide insertion leading a premature stop codon 58 amino acids downstream of the mutation. The other novel mutation was identified in IL2RG gene (c.829G>A) in patient 10. It was also a nonsense single nucleotide change which results in a stop codon instead of tryptophan. All information about these mutations is given in Fig. 1 .
In patient 1, a previously described and most likely causative RAG1 mutation (c.2322G>A) was identified [21] . In patient 4, two distinct RAG1 variants were found as compound heterozygous (c.537G>A and c.1443C>T) with predicted damaging effects 'possibly damaging' (PolyPhen, score: 0643) and 'deleterious' (SIFT, score: 0). The first missense variant causes an amino acid change of arginine to glycine. It affects the B1 basic domain of the protein which serves as binding site for the nuclear transport proteins [22] . The second missense variant leads to an alanine-to-valine change which was in the nanomer DNA-binding region of the protein [23] , (Fig. 1) . All prediction tool scores of missense mutations are given in Table S4 .
In patient 5, we detected a heterozygous variant (c. 835G>A) in TERT. The Telomerase Reverse Transcriptase (TERT) gene encodes the enzyme which is responsible for catalyzing the addition of telomere repeats [24] . Mutations in TERT may lead to bone marrow failure (dyskeratosis congenita [25] ). Dyskeratosis congenita is an inherited bone marrow failure syndrome characterized by mucocutaneous triad of oral leukoplakia, nail dystrophy and abnormal skin pigmentation [26] . In the study of Vulliamy et al., [27] the same c.835G>A variant was found in five of 80 patients with dyskeratosis congenita and eight healthy controls from a total number of 197, suggesting that it may not be disease-causing. In support of this, the phenotype of our patient was T-B-SCID without bone marrow failure or any other characteristic feature of DC.
Discussion
Primary immunodeficiencies are a heterogeneous group of disorders with a broad range of clinical symptoms. Most of primary immunodeficiency diseases are monogenic disorders and inherited as autosomal recessive (AR) forms [28] . SCID is a very severe form of PID, and early diagnosis can be life-saving. HSCT and, in selected cases, gene therapy are the curative treatment approaches for SCID [29, 30] . Thus, determining the underlying genetic defect is important for these patients. In addition, understanding the molecular pathophysiology of a PID contributes the development of new therapeutic approaches.
Next-generation sequencing-based approaches may be powerful to facilitate molecular diagnosis [31, 32] . The analysis of one human genome with NGS is less timeconsuming and costly than with many other sequencing technologies. In particular, NGS-based targeted DNA sequencing methods became the most useful platform for molecular diagnosis of the diseases like PIDs [33] . We aimed to search the underlying genetic defects of 19 Turkish SCID patients and used a targeted sequencing panel that includes 356 PID-related genes. This method allows assessing a large number of PID-associated genes and provides to multiplex up to 96 patients in a run. The overall coverage of targeted regions was sufficiently high ranging from 97.47% to 99.62%. The average coverage of all patients was 98.31%. In addition, we calculated the coverage of SCID and SCID-like genes which was at minimum 97.3%. All these data highlight that our panel was reliable to detect genetic variants. Despite high overall coverage, 15 genes were not well covered. A possible reason for the low coverage could be high GC content or the existence of pseudogenes as described for PMS2, NCF1 and IKBKG [34] [35] [36] . Another reason for insufficient coverage could be the applied sequencing strategy employing a 100-bp paired-end run. However, longer read lengths may be an option to cover the gaps or re-optimized probe design may be used for further studies.
We obtained the sequencing data from 19 patients and determined the underlying genetic defects in six patients. Finally, after a validation processes with capillary sequencing we identified probable disease-causing genetic defects in six patients with the rate of 32% and of those four mutations were described for the first time. In recent reports of Nijman et al. and Stoddard et al., the investigators were able to identify potentially PID-causing mutations in four of 26 (15%) and 18 of 120 (15%) PID patients, respectively [19, 37] . Hamoud Al-Mousa et al.
[38] also determined disease-causing defects in 35 patients of 139 (25%). In this report, they identified eight diseasecausing mutations in a total of 27 SCID patients (30%). We identified a genetic diagnosis in six of 19 patients (32%); however, our study included only SCID patients. To our knowledge, this is the first study on SCID patients using a targeted sequencing approach. We expected to find disease-causing mutations at least in 50% of our patients. However, our data suggest that particularly in populations with high degree of consanguinity and expected autosomal recessive defects, a number of novel genetic aetiologies underlying SCID phenotypes are yet to be uncovered. As an alternative explanation, although the overall total coverage and also the coverage of SCID and CID genes were high in our study, potentially disease-causing mutations may have been located in small regions not well covered with our approach. Another possibility could be that the genetic defects in the patients are located in promotor regions or introns, which could only be addressed using more extensive approaches such as whole genome sequencing.
Relative incidences of PIDs with AR inheritance are higher than autosomal dominant (AD) in Turkey compared with Western countries due to high rate of consanguineous marriages. The ratio of autosomal recessive inherited SCID patient was more than 80% in Turkey, while it was 20% in the SCID cohort of Duke University, USA [39] . Six mutations identified in our study were AR inherited and found in RAG1 and JAK3 genes. We identified only one X-linked recessive mutation in IL2RG gene in a male patient. In the countries which have high consanguineous marriages such as Israel and Egypt, AR forms of SCID are more frequent like Turkey [40] . Dalal et al. [41] searched for genetic defects in patients with T-B-SCID or Omenn syndrome by Sanger sequencing, and they identified five causative RAG1 or RAG2 mutations among 16 patients (% 31). Our study included ten T-B-SCID patients, and we found causative RAG1 mutations in three patients (30%). The percentages of RAG genes mutations were similar in two populations with high rate of consanguineous marriage. As determination of PID phenotypes is important for genetic counselling and therapy, particularly HSCT and gene therapy for SCID patients, NGS methods will help to identify disease phenotypes at an increasing rate.
In conclusion, we established a fast, novel strategy for screening of patients with PID. Our results indicate that this method can be applied to efficiently identify PIDcausing defects. NGS-based technologies can facilitate the genetic diagnosis of the patients particularly with complicated clinical PID phenotypes. New targeted panels including additional candidate genes might be used for further studies.
